Ad
Tuesday, 31 October 2017
AstraZeneca wins early U.S. approval for blood cancer drug
LONDON (Reuters) - AstraZeneca has won U.S. approval for a new blood cancer drug several months earlier than expected, boosting its oncology portfolio - and requiring it to pay $1.5 billion to shareholders in the biotech company that first discovered the medicine.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment